155 related articles for article (PubMed ID: 37103079)
81. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
82. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
Iioka F; Izumi K; Kamoda Y; Akasaka T; Ohno H
Int J Clin Oncol; 2016 Jun; 21(3):498-505. PubMed ID: 26463529
[TBL] [Abstract][Full Text] [Related]
83. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
[TBL] [Abstract][Full Text] [Related]
84. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.
Friedberg JW; Unger JM; Burack WR; Gopal AK; Raju RN; Nademanee AP; Kaminski MS; Li H; Press OW; Miller TP; Fisher RI
Br J Haematol; 2014 Aug; 166(3):382-9. PubMed ID: 24749780
[TBL] [Abstract][Full Text] [Related]
85. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
86. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
87. [Risk of reactivation of hepatitis B in patients with the lymphoma HBsAg negative , anti-HBc positive treated with rituximab-CHOP].
Pariente A
Rev Prat; 2014 Mar; 64(3):324. PubMed ID: 24851363
[No Abstract] [Full Text] [Related]
88. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
Pettengell R; Johnsen HE; Lugtenburg PJ; Silvestre AS; Dührsen U; Rossi FG; Schwenkglenks M; Bendall K; Szabo Z; Jaeger U
Support Care Cancer; 2012 Mar; 20(3):647-52. PubMed ID: 22101611
[TBL] [Abstract][Full Text] [Related]
89. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
Baech J; Hansen SM; Lund PE; Soegaard P; Brown PN; Haaber J; Jørgensen J; Starklint J; Josefsson P; Poulsen CB; Juul MB; Torp-Pedersen C; El-Galaly TC
Br J Haematol; 2018 Dec; 183(5):717-726. PubMed ID: 30406945
[TBL] [Abstract][Full Text] [Related]
90. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
91. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.
González-Barca E; Canales MA; Salar A; Ferrer S; Domingo-Domenech E; Vidal MJ; Grande C; Bargay J; Gardella S; Oriol A; Briones J; García-Frade J; Bello JL; Sánchez-Blanco JJ; Peñalver FJ; Tomás JF; Asensio A; López A; Caballero D;
Acta Haematol; 2016; 136(2):76-84. PubMed ID: 27188649
[TBL] [Abstract][Full Text] [Related]
92. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M
Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203
[TBL] [Abstract][Full Text] [Related]
93. Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
Lee GW; Kang JH; Kim IS; Kim HG; Ko GH; Lee JH; Kim DC; Song DH; Yang JW; Lee JS
Leuk Lymphoma; 2009 Dec; 50(12):1992-8. PubMed ID: 19860620
[TBL] [Abstract][Full Text] [Related]
94. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
95. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
He HX; Gao Y; Bai B; Wang XX; Li JB; Huang C; Mao JY; Ping LQ; Rong QX; He YX; Huang H; Cai QQ; Li ZM; Jiang WQ; Huang HQ
Cancer Med; 2021 Nov; 10(21):7650-7664. PubMed ID: 34581023
[TBL] [Abstract][Full Text] [Related]
96. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
97. [Association of Geriatric Nutritional Risk Index with Adverse Events and Time to Treatment Failure in Malignant Lymphoma Patients Treated with(R-)EPOCH].
Kikuchi K; Yama K; Misaka H; Takeda G; Watanabe T; Souma T; Harada T; Lang L; Yamawaki F; Saga T; Ishihara T; Sato H
Gan To Kagaku Ryoho; 2023 Jun; 50(6):701-705. PubMed ID: 37317604
[TBL] [Abstract][Full Text] [Related]
98. Association of Geriatric Nutritional Risk Index With Adverse Event and Treatment Duration in Adjuvant Chemotherapy for Patients With Colorectal Cancer.
Shimizu A; Fukasawa M; Endo R; Nakamura T; Yamada S; Fujibayashi R; Kikuchi K; Tanaka M; Hasegawa I; Sato H
In Vivo; 2024; 38(1):453-459. PubMed ID: 38148079
[TBL] [Abstract][Full Text] [Related]
99. Association of Geriatric Nutritional Risk Index With Immune Checkpoint Inhibitor Treatment Duration and Adverse Events in Lung Cancer.
Shimizu A; Fukasawa M; Mitani K; Goto K; Wakamoto A; Hatsuyama T; Hoshi T; Hasegawa I; Sato H
In Vivo; 2024; 38(1):418-424. PubMed ID: 38148096
[TBL] [Abstract][Full Text] [Related]
100. Cyclophosphamide exposure via sweat of patients receiving CHOP therapy.
Miyazawa M; Yamashita R; Ichinohe Y; Kohzai Y; Kishimoto K
J Oncol Pharm Pract; 2023 Oct; 29(7):1646-1651. PubMed ID: 36514300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
